Ekow Essien

Ekow Essien

Auto-generated profile, based on publicly available information

Ekow Essien

Department of Internal Medicine, Advocate Aurora Health Care, Milwaukee, WI, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Journal of Cardiovascular Intervention
Verified
Journal Article
Open access
PDF file
EEEkow Essien
Ekow Essien
AAAbena Agyekum
Abena Agyekum
ACAbraham Carboo
Abraham Carboo
GAGloria Amoako
Gloria Amoako
KNKarldon Nwaezeapu
Karldon Nwaezeapu
GAGodbless Ajenaghughrure
Godbless Ajenaghughrure
Essien E, et al. J Cardiovasc Interv. 2025 Aug;5:e2. https://doi.org/10.54912/jci.2025.0029

1 June 2026 in Sleep Science
Verified
Journal Article
Open access
EEEkow Essien
Ekow Essien
AAAbena Agyekum
Abena Agyekum
ACAbraham Carboo
Abraham Carboo
GAGloria Amoako
Gloria Amoako
JOJustice Owusu-Achiaw
Justice Owusu-Achiaw
SGSamuel Bisilki Governor
Samuel Bisilki Governor
Obstructive sleep apnea (OSA) increases cardiovascular disease risk through systemic inflammation, particularly through elevated C-reactive protein (CRP). This study investigated whether CRP stratification predicts mortality and cardiovascular events in OSA patients. We conducted a retrospective cohort analysis using the TriNetX Research Network, encompassing electronic health records from 130 healthcare institutions. Adults (ages 18–90 years) with OSA were stratified by CRP concentration: elevated (≥ 3.0 mg/L) versus low (≤ 2.9 mg/L). After propensity score matching for demographics and comorbidities, 240,727 participants per cohort were followed for five years. Primary outcome was all-cause mortality; secondary outcomes included cardiovascular events, arrhythmias, and acute kidney injury. Elevated CRP was associated with significantly higher all-cause mortality (11.3% versus 7.0%; HR 1.695, 95% CI 1.662–1.727; p < 0.001). The elevated CRP group demonstrated heightened cardiovascular risk: cardiogenic shock (1.0% versus 0.5%; HR 2.003), heart failure (9.8% versus 6.5%; HR 1.594), pulmonary hypertension (4.9% versus 3.4%; HR 1.508), and acute kidney injury (11.0% versus 6.4%; HR 1.825), all p < 0.001. Arrhythmic complications were also increased: atrial fibrillation/flutter (6.3% versus 4.8%; HR 1.372) and ventricular tachycardia (2.3% versus 1.8%; HR 1.388), both p < 0.001. Elevated CRP constitutes a robust predictor of mortality and cardiovascular morbidity in OSA populations. Assessment of inflammatory biomarkers may enhance risk stratification, informing intensified monitoring and targeted therapeutic interventions.

1 October 2026 in International Journal of Diabetes and Technology
Verified
Journal Article
Open access
EEEkow Essien
Ekow Essien
AAAbena Agyekum
Abena Agyekum
GAGloria Amoako
Gloria Amoako
SGSamuel B. Governor
Samuel B. Governor
Background: Elevated fibrinogen is associated with increased cardiovascular risk; however, its prognostic significance in patients with coexisting type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) is not well established. Aim: The aim is to evaluate whether elevated fibrinogen levels are independently associated with increased 5-year risk of all-cause mortality and major cardiovascular and renal events in patients with T2DM and established CAD, using a large propensity-matched real-world cohort. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network (130 healthcare organizations). Adults aged 18–90 years with T2DM and CAD were stratified by fibrinogen level into high (≥401 mg/dL) and low (≤400 mg/dL) groups. After propensity score matching, 92,684 patients were included in each cohort and followed for 5 years. The primary outcome was all-cause mortality. Secondary outcomes included heart failure, acute kidney injury (AKI), ventricular tachycardia, cerebrovascular disease, pulmonary embolism, acute myocardial infarction (AMI), and chronic kidney disease (CKD). Results: The high-fibrinogen cohort had greater 5-year mortality compared with the low-fibrinogen cohort (36.6% vs. 30.7%; hazard ratio [HR]: 1.267, 95% confidence interval [CI]: 1.247–1.287; P < 0.001). Elevated fibrinogen was also associated with higher risks of heart failure (HR: 1.119), AKI (HR: 1.242), cerebrovascular disease (HR: 1.127), AMI (HR: 1.204), and CKD (HR: 1.186) (all P < 0.001). Conclusion: Among patients with T2DM and CAD, elevated fibrinogen independently predicts increased mortality and major cardiovascular and renal events, supporting its role as a prognostic biomarker in this high-risk population.

11 June 2026 in Journal of Updates in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
EEEkow Essien
Ekow Essien
AAAbena Agyekum
Abena Agyekum
ACAbraham Carboo
Abraham Carboo
GAGloria Amoako
Gloria Amoako
JOJustice Owusu-Achiaw
Justice Owusu-Achiaw
Association between Glycemic Control and Adverse Outcomes in Atrial Fibrillation: Evidence from a Large Real-world Cohort - Journal of Updates in Cardiovascular Medicine

20 October 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
SGSamuel Bisilki Governor
Samuel Bisilki Governor
DDDavid M. Dávila‐García
David M. Dávila‐García
EREliut Rivera-Segarra
Eliut Rivera-Segarra
LFLindsey M. Filiatreau
Lindsey M. Filiatreau
NTNelmit Tollinchi-Natali
Nelmit Tollinchi-Natali
VDVictor G. Dávila‐Román
Victor G. Dávila‐Román
Background: Adults with serious mental illness (SMI), type 2 diabetes, and obesity have elevated cardiovascular risk. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have established cardiometabolic benefits in the general population, but their effects in SMI are unclear. We evaluated whether GLP‐1RA use was associated with lower risks of incident myocardial infarction (MI), heart failure (HF), and all‐cause death. Methods: This was a retrospective propensity score–matched cohort study of 218 043 adults with SMI, type 2 diabetes, obesity, and active antipsychotic or antidepressant medications in the TriNetX database (73 health care organizations). Outcomes were incident MI, HF, and all‐cause death at 1 and 3 years. The primary exposure was GLP‐1RA use versus nonuse; secondary analyses examined semaglutide or tirzepatide. Exploratory analyses evaluated sex, race, and sodium–glucose cotransporter‐2 inhibitor and dipeptidyl peptidase‐4 inhibitor use. Results: GLP‐1RA use was associated with lower risks of incident MI, HF, and all‐cause death. Risk differences at 1 and 3 years were −0.007 and −0.010 for MI, −0.011 and −0.018 for HF, and −0.039 and −0.065 for death (all P <0.001). Semaglutide or tirzepatide use was also associated with lower risks of MI, HF, and death (all P <0.001). Findings were directionally consistent after accounting for sodium–glucose cotransporter‐2 inhibitor and dipeptidyl peptidase‐4 inhibitor use. Conclusions: Adults with treated SMI, type 2 diabetes, and obesity using GLP‐1RAs, particularly semaglutide or tirzepatide, had significantly reduced 1‐ and 3‐year risks of incident MI, HF, and all‐cause death versus nonusers. These pooled associations should be interpreted in the context of SMI's clinical heterogeneity and the limitations of administrative case ascertainment.